Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.77 |
| ▸ | IL1RN | P18510 | 1/20 | 0.77 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | PIM1 | P11309 | 6/20 | 0.69 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.69 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 5/20 | 0.67 |
| ▸ | GSK3B | P49841 | 2/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.60 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.59 |
| ▸ | METAP1 | P53582 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212026 | 1.00 | MYC (0.77) | MYCIL1RNERAP1TDP1PIM1 | |
| SCHEMBL212025 | 1.00 | MYC (0.77) | MYCIL1RNERAP1TDP1PIM1 | |
| SCHEMBL212735 | 0.87 | GPR35 (0.70) | MYCIL1RNERAP1TDP1PIM1 | |
| SCHEMBL212734 | 0.87 | GPR35 (0.70) | MYCIL1RNERAP1TDP1PIM1 | |
| SCHEMBL212733 | 0.87 | GPR35 (0.70) | MYCIL1RNERAP1TDP1PIM1 | |
| SCHEMBL6416668 | 0.87 | MRE11 (0.70) | MYCIL1RNERAP1TDP1PIM1 | |
| SCHEMBL6416669 | 0.87 | MRE11 (0.70) | MYCIL1RNERAP1TDP1PIM1 | |
| SCHEMBL6962632 | 0.87 | MYC (1.00) | MYCIL1RNERAP1TDP1RAB9A | |
| SCHEMBL6962628 | 0.87 | MYC (1.00) | MYCIL1RNERAP1TDP1RAB9A | |
| SCHEMBL12961169 | 0.87 | MYC (1.00) | MYCIL1RNERAP1TDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7872027-B2 | Low molecular weight Myc-max inhibitors | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-01-18 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| US-20070203188-A1 | oncoprotein gene expression inhibitors such as 5-[(4-chlorophenyl)methylidene]-3-(piperidin-1-ylmethyl)-2-sulfanylidene-1,3-thiazolidin-4-one, used as antiproliferative and anticarcinogenic agents | UNIVERSITY OF PITTSBURGH (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1429763-B1 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-05-30 | — | — | EP | disclosed |
| US-7022722-B2 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20060047000-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS, INC. (US) | 2006-03-02 | — | — | US | disclosed |
| US-20030236227-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS | 2003-12-25 | — | — | US | disclosed |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-04-03 | — | — | US | disclosed |
| WO-2003024943-A2 | ARYL DERIVATIVES FOR THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | ARYX THERAPEUTICS (US) | 2003-03-27 | — | — | WO | disclosed |
| US-6518268-B1 | Telomerase inhibitors and methods of their use | GERON CORPORATION | 2003-02-11 | — | — | US | disclosed |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-02-06 | — | — | US | disclosed |
| EP-1276730-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYx Therapeutics (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001081328-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYX THERAPEUTICS (US) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001002377-A9 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORP (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1109796-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002377-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236227-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | MYC 2827/4885IL1RN 3669/4885ERAP1 392/4885 |
| US-20070203188-A1 | oncoprotein gene expression inhibitors such as 5-[(4-chlorophenyl)methylidene]-3-(piperidin-1-ylmethyl)-2-sulfanylidene-1,3-thiazolidin-4-one, used as antiproliferative and anticarcinogenic agents | MYC, MYCBP, MAX | MYC 1/4885IL1RN 2176/4885ERAP1 1356/4885 |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | MYC 2827/4885IL1RN 3669/4885ERAP1 392/4885 |
| US-20060047000-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | MYC 2827/4885IL1RN 3669/4885ERAP1 392/4885 |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | MYC 2827/4885IL1RN 3669/4885ERAP1 392/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | MYC 2998/4885IL1RN 209/4885ERAP1 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.